Multiple sclerosis, IL-12 serum level, Single nucleotide polymorphism.Multiple sclerosis (MS) is a chronic neurodegenerative disease that results from interaction between genetic, epigenetic, and environmental factors, and affects especially young adults. Serum level and single nucleotide polymorphism (SNP) of Interleukin-12 (IL-12) were determined in 68 relapsing-remitting MS Iraqi patients and 20 healthy individuals, matched patients for ethnicity, age and gender. The patients were distributed into IFNβ pre-and postmedicated patients, in addition, extended disability status scale (EDSS) was also applied as a parameter for distribution. The results indicated that there were significant differences in serum levels of IL-12 among the three investigated groups; pre-and post-medicated patients and controls (35.9 ± 1.6 vs. 29.5 ± 2.4 vs. 22.7 ± 2.9 pg/ml, respectively). However, there was no significant effect of EDSS on the level of IL-12 in pre-and post-medicated patients. IL12B gene SNP at position +1188 was presented with three genotypes (AA, AC and CC), which showed a significant difference between the observed and expected genotype frequencies (p ≤ 0.01) in patients, while a good agreement with Hardy-Weinberg equilibrium was observed in controls. However, there was no significant variation between patients and controls in the distribution of IL12B +1188 allele and genotype frequencies; although CC genotype was observed with a frequency of 17.9% in MS patients, while none of the controls possessed this genotype, and the odds ratio of such difference was 9.23. A significant impact of IL12B +1188 SNP on IL-12 serum level was recorded in MS patients carrying CC and AC genotypes (27
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.